Business Wire

SES/IMS

15.12.2021 08:52:11 CET | Business Wire | Press release

Share
IMS and SES to Expand Internet Connectivity to Underserved Colombian Communities With O3b mPOWER

SES’s satellite-based trunking services will enable leading Colombian fibre optic networks service provider Integra Multisolutions (IMS) to extend and enhance fibre-like connectivity for Colombian municipalities with fewer than 100,000 inhabitants located out of the reach of terrestrial infrastructure, SES announced today. The new service will begin on SES’s O3b medium earth orbit (MEO) constellation and later migrate onto O3b mPOWER, SES’s next-generation MEO system, in 2022 when service will expand to additional cities.

The first site to be connected will be Puerto Leguizamo, a municipality located in the Putumayo Department in the southern border region of the country. SES and IMS will go on to deliver service to other sparsely populated cities across Colombia that experience poor or inconsistent connectivity services.

SES’s Trunk mPOWERED service will equip IMS to enable local Internet service providers to serve a combination of enterprise, residential, MNO and civilian government projects. IMS is among the first companies in Latin America to sign up for the O3b mPOWER system, which can deliver low-latency, high-speed, uncontended services from tens of megabits to multiple gigabits per second to a single site.

According to the Colombian Ministry of Telecommunications, fixed broadband subscriptions in the country reached 8.22 million in 2021, which translates to 16.10 subscriptions per 100 people. However, the National Administrative and Statistics Department (Dane) revealed earlier this year the results of the Survey of Information and Communication Technologies in Households (ENTIC Hogares) showing only 56.5% of the households surveyed have an internet connection. The survey identified an important difference between households in the main cities, where 66.6% have internet access, and those in rural and dispersed areas, where only 23.9% of the households do. The Putumayo Department is among the regions with challenges to access reliable connectivity services.

“By working together with SES, we are able to quickly and cost-effectively expand our network in underserved and tough-to-reach areas helping to address the digital divide for these communities,” said Juan Carlos Hernandez Mendoza, CEO of IMS Group. “Our goal is to provide our end users the best quality of service across Colombia, which means access to high-performing services at all times, no matter where they are. The capabilities of the proven O3b MEO fleet, and the scalability and flexibility of the upcoming O3b mPOWER services combined with SES satellite network and IMS fibre optics networks expertise, allow us to achieve exactly that.”

“Our multi-orbit satellite solutions have been bringing reliable connectivity services across Colombia for almost 10 years,” said Omar Trujillo, Americas Vice President of Fixed Data Sales at SES. “We are delighted to partner with IMS to extend terrestrial networks with the revolutionary capabilities of the O3b mPOWER constellation and deliver fibre-like Internet access to Colombians wherever they live.”

Follow us on:
TwitterFacebookYouTubeLinkedInInstagram
Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

About IMS

IMS was created in 2016, since then IMS is becoming the main PARTNER for all the small and medium Internet Service Providers in Colombia through terrestrial telecom technologies specialized in fiber optic networks, Networking Engineering, ISP Tech Solutions, supply chain, and many more. Currently IMS has more than 100,000 kilometres of available fiber throughout Colombia and sells more than 300 Gbps of fiber optic capacity to more than 250 corporate customers, becoming a very important provider for internet carriers in the region. For more information about IMS go to www.ims.net.co .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye